DCDC1 (KIAA1493): A Potent Drug Target and Potential Biomarker

Target Name: DCDC1

NCBI ID: G341019

DCDC1

DCDC1 (KIAA1493): A Potent Drug Target and Potential Biomarker

DCDC1 (KIAA1493) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell-cycle and is involved in various cellular processes, including cell growth, apoptosis, and development. The discovery of DCDC1 as a potential drug target has significant implications for the development of new treatments for various diseases. In this article, we will explore the biology of DCDC1, its potential as a drug target, and its potential as a biomarker for disease diagnosis and prediction.

DCDC1: A Non-Coding RNA Molecule

DCDC1 is a non-coding RNA molecule that was identified by bioinformatic analysis of genomic RNA sequencing data. It is expressed in various tissues and cell types and is involved in the regulation of cellular processes, including cell growth, apoptosis, and development. DCDC1 is a small molecule that can interact with other molecules in the cell to regulate their activity and ultimately control cellular processes.

DCDC1 as a Potential Drug Target

The discovery of DCDC1 as a potential drug target has significant implications for the development of new treatments for various diseases. One of the key advantages of DCDC1 as a drug target is its involvement in various cellular processes that are disrupted in many diseases, including cancer, neurodegenerative diseases, and developmental disorders. DCDC1 has been shown to play a role in the regulation of cell-cycle progression, apoptosis, and cellular signaling pathways, which are often disrupted in these diseases.

In addition, DCDC1 has been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed. This is important for diseases such as cancer, where the growth of new blood vessels is a key factor in the development and progression of the disease.

DCDC1 as a Potential Biomarker

The discovery of DCDC1 as a potential drug target has also implications for the development of new biomarkers for disease diagnosis and prediction. DCDC1 has been shown to be involved in the regulation of various cellular processes, including cell growth, apoptosis, and development. This makes it an attractive candidate for use as a biomarker for disease diagnosis and prediction.

One of the key advantages of DCDC1 as a biomarker is its potential to be used in non-invasive diagnostic tests. DCDC1 is expressed in various tissues and cell types and can be used as a protein or RNA biomarker for diagnostic tests. This is important for diseases that are currently difficult to diagnose, such as cancer, where a non-invasive diagnostic test would be valuable.

In addition, DCDC1 has also been shown to be involved in the regulation of cellular signaling pathways, which makes it an attractive candidate for use as a biomarker for disease diagnosis and prediction. The regulation of cellular signaling pathways is a key aspect of cellular biology and is involved in the development and progression of many diseases.

Conclusion

In conclusion, DCDC1 (KIAA1493) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its involvement in various cellular processes, including cell growth, apoptosis, and development makes it an attractive candidate for use as a new drug or biomarker. The discovery of DCDC1 has significant implications for the development of new treatments for various diseases and has the potential to revolutionize the field of biomarker research. Further research is needed to fully understand the biology of DCDC1 and its potential as a drug target and biomarker.

Protein Name: Doublecortin Domain Containing 1

Functions: Microtubule-binding protein which plays an important role in mediating dynein-dependent transport of RAB8A-positive vesicles to the midbody during cytokinesis (PubMed:22159412)

The "DCDC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DCDC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets